Inflammatory disease drug developer Inflazome, based on research at University of Queensland and Trinity College Dublin, has added $45.6m in series B capital to its coffers.

Inflazome, an Ireland-based biotechnology spinout of University of Queensland that is developing drugs to block harmful inflammation, closed a €40m ($45.6m) series B round on Monday led by VC firm Forbion Capital Partners. Novartis Venture Fund, an investment arm of pharmaceutical firm Novartis, also participated, as did Longitude Capital and Fountain Healthcare Partners. Inflazome is developing therapies…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.